miR-126 regulated breast cancer cell invasion by targeting ADAM9

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6547-6553

  Wang, Cheng Zheng ^a   Yuan, Peng ^a   Li, Yin ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

ADAM9; Breast cancer; Invasion; MiR 126

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN126 MICRORNA, HUMAN;

BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING;

ADAM PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MICRORNAS; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84938632069     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Matsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg 2013; 148: 971-980.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Cyr AE, Margenthaler JA. Molecular profiling of breast cancer. Surg Oncol Clin N Am 2014; 23: 451-62.
5. Gradishar WJ. Treatment of metastatic breast cancer. J Natl Compr Canc Netw 2014; 12: 759-61.
6. Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press) 2014; 6: 1-13.
7. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104.
8. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20.
9. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013; 73: 473-7.
10. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013; 19: 4477-87.
11. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, Marmé F, Turchinovich A, Sinn P, Sohn C, Junkermann H, Schneeweiss A, Burwinkel B. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One 2013; 8: e76729.
12. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, Qin Y. Endothelial specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 2011; 351: 157-64.
13. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 2014; 7: 9-18.
14. Klein T, Bischoff R. Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res 2011; 10: 17-33.
15. Wagstaff L, Kelwick R, Decock J, Edwards DR. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front Biosci (Landmark Ed) 2011; 16: 1861-72.
16. Hatkevich T, Ramos J, Santos-Sanchez I, Patel YM. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 2006; 312: 331-9.
17. Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, Fujita H, Nagai E, Tanaka M. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007; 27: 793-9.
18. Lendeckel U, Kohl J, Arndt M, Carl McGrath S, Donat H, Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005; 131: 41-8.
19. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20.
20. Plank M, Maltby S, Mattes J, Foster PS. Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs. Clin Exp Allergy 2013; 43: 981-99.
21. Khella HW, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, Lee JY, Ordon M, Stewart R, Jewett MA, Yousef GM. Low expression of miR-126 Is a prognostic marker for metastatic clear cell renal cell carcinoma. Am J Pathol 2015; 185: 693-703.
22. Yang Y, Song KL, Chang H, Chen L. Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer. Diagn Pathol 2014; 9: 1001.
23. Liu Y, Zhou Y, Feng X, Yang P, Yang J, An P, Wang H, Ye S, Yu C, He Y, Luo H. Low ex-pression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer 2014; 53: 358-65.
24. Hafez MM, Hassan ZK, Zekri AR, Gaber AA, Al Rejaie SS, Sayed-Ahmed MM, Al Shabanah O. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev 2012; 13: 591-598.
25. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
26. Jiang L, He A, Zhang Q, Tao C. miR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. Tumour Biol 2014; 35: 12645-54.
27. Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C. Micro-RNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 2014; 110: 2945-54.
28. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, Masamune A, Kikuta K, Kume K, Shimosegawa T. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 2012; 10: 3-10.
29. Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res 2014; 74: 5229-43.
30. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 2004; 64: 4190-6.
31. Micocci KC, Martin AC, Montenegro Cde F, Durante AC, Pouliot N, Cominetti MR, Selistre-de-Araujo HS. ADAM9 silencing inhibits breast tumor cell invasion in vitro. Biochimie 2013; 95: 1371-8.
32. Fry JL, Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res 2010; 70: 8187-98.